News

Concord Biotech announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at the company`s API manufacturing facility in Limbasi. The inspection took place from 08 June to 12 June 2026, and was concluded successfully.

Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA).According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.

Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Concord Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 7.55 per equity Share (i.e. 755%) , subject to the approval of the shareholders.

Net profit of Concord Biotech declined 36.75% to Rs 88.79 crore in the quarter ended March 2026 as against Rs 140.39 crore during the previous quarter ended March 2025. Sales declined 24.15% to Rs 326.08 crore in the quarter ended March 2026 as against Rs 429.88 crore during the previous quarter ended March 2025.For the full year,net profit declined 29.79% to Rs 260.91 crore in the year ended March 2026 as against Rs 371.64 crore during the previous year ended March 2025. Sales declined 12.10% to Rs 1054.89 crore in the year ended March 2026 as against Rs 1200.09 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales326.08429.88 -24 1054.891200.09 -12 OPM %36.2943.94 -34.8342.08 - PBDT133.62198.16 -33 422.39548.93 -23 PBT114.08183.54 -38 347.93494.55 -30 NP88.79140.39 -37 260.91371.64 -30 Powered by Capital Market - Live News